<div id="readability-page-1">04:38 AM EST, 11/26/2025 (MT Newswires) -- Nyxoah SA ( NYXH ) said Wednesday that the US Centers for Medicare &amp; Medicaid Services has approved a new reimbursement rule, increasing the reimbursement rate applicable to the company's Genio neurostimulation therapy for obstructive sleep apnea.Effective Jan. 1, 2026, hospital outpatient department reimbursement for the code applicable to Genio will rise 48% to $45,000, while ambulatory surgery centers facility reimbursement will increase 58% to $42,373, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

NYXH

Nyxoah SA announced that the US Centers for Medicare & Medicaid Services has approved a new rule increasing reimbursement rates for its Genio neurostimulation therapy for obstructive sleep apnea. Effective January 1, 2026, hospital outpatient department reimbursement will rise 48% to $45,000, and ambulatory surgery centers facility reimbursement will increase 58% to $42,373.

Nyxoah Gets Increased Reimbursement Framework for Genio Therapy Under New CMS Rule